Jardiance sales ease Boehringer's patent-loss pain by Kyle Blankenship Wednesday, April 17, 2019 As sales of blockbuster lung drug Spiriva flagged in 2018, Boehringer Ingelheim needed a boost from other divisions. Turns out diabetes was the key.
AZ's Farxiga won its EU nod in Type 1. How will it fare at FDA? by Angus Liu Tuesday, March 26, 2019 Increased incidence of diabetic ketoacidosis in Type 1 patients, an issue raised at Zynquista's AdCom meeting, has shown up in other SGLT trials.
AZ's Farxiga cuts risks in heart attack, heart failure patients by Eric Sagonowsky Monday, March 18, 2019 After AstraZeneca released overall CV outcomes results for Farxiga, the company has dug further into the data and presented two subanalyses on Monday.
Lilly lays out sunny 2019 forecast driven by growth of new meds by Arlene Weintraub Wednesday, December 19, 2018 Lilly provided a forecast for next year that beat analysts’ expectations—welcome news as blockbuster Cialis faces generic rivals.
J&J backs new Invokana CV nod with series of awareness tweets by Beth Snyder Bulik Wednesday, November 14, 2018 Johnson & Johnson's Janssen is using Twitter to get the word out about the link between Type 2 diabetes and cardiovascular risks.
Farxiga lowers hospitalizations for heart failure or CV death by Eric Sagonowsky Monday, November 12, 2018 With outcomes data showing Farxiga lowers hospitalizations for heart failure or CV deaths against placebo, AZ plans to file for a new FDA label.
With Cialis under pressure, Lilly's new launches step up by Eric Sagonowsky Tuesday, November 6, 2018 Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.
J&J's diabetes drug Invokana bags long-awaited cardio nod by Carly Helfand Wednesday, October 31, 2018 It’s been more than a year since J&J showed Invokana could improve heart safety, but the company's reps can finally tout those benefits.
AstraZeneca steps up its Farxiga game with CV outcomes win by Eric Sagonowsky Monday, September 24, 2018 With data showing Farxiga can reduce hospitalizations for heart failure or CV deaths against placebo, AZ plans to seek a label update.
FDA slaps gangrene warning on SGLT2 diabetes drugs by Arlene Weintraub Thursday, August 30, 2018 The FDA has raised red flags about a potentially serious flesh-eating disease in patients taking SGLT2 inhibitors.
